Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-038663
Filing Date
2020-08-10
Accepted
2020-08-10 09:00:47
Documents
77
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvmd-10q_20200630.htm 10-Q 3096996
2 EX-31.1 rvmd-ex311_9.htm EX-31.1 17975
3 EX-31.2 rvmd-ex312_7.htm EX-31.2 18146
4 EX-32.1 rvmd-ex321_10.htm EX-32.1 8488
5 EX-32.2 rvmd-ex322_8.htm EX-32.2 8537
  Complete submission text file 0001564590-20-038663.txt   10318550

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rvmd-20200630.xml EX-101.INS 2301437
7 XBRL TAXONOMY EXTENSION SCHEMA rvmd-20200630.xsd EX-101.SCH 69921
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvmd-20200630_cal.xml EX-101.CAL 74148
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvmd-20200630_def.xml EX-101.DEF 233500
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmd-20200630_lab.xml EX-101.LAB 516736
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmd-20200630_pre.xml EX-101.PRE 391570
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39219 | Film No.: 201087360
SIC: 2836 Biological Products, (No Diagnostic Substances)